



Indiana University Health Ball Memorial Cancer Center Oncology Open Clinical Trials.

BREAST CANCERS

NSABP Protocol B-55 PI-Joseph Spahr, MD (NCT 02032823)

Coordinator-Cathleen Carlos

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Center Phase III Study to Assess the Efficacy and Safety of Olaparib vs Placebo as Adjuvant Treatment in Patients with Germline BRCA 1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

NRG-BR002 PI-Yunjie Lin, MD (NCT 02364557)

Coordinator-Angie Patterson

A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer

A011401 (BWEL) PI-Maitri Kalra, MD (NCT 02750826)

Coordinator-Cathleen Carlos

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women in Early Breast Cancer

SWOG S1703 PI-Maitri Kalra, MD (NCT 03723928)

Coordinator-Cathleen Carlos

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer

CCTG MA.39 TAILOR RT PI-Yunjie Lin, MD

Coordinator-Angie Patterson

A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

THORACIC CANCERS

CALGB 30610/RTOG 0538 PI-Yunjie Lin, MD (NCT 00632853)

Coordinator-Angie Patterson

A Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin or Carboplatin and Etoposide

SOLID TUMORS

LUN15-233 PI-Joseph Spahr, MD (NCT 03041181)

Coordinator-Angie Patterson

Randomized Phase II Trial of single agent chemotherapy plus Nivolumab or single agent chemotherapy alone in patients with advanced squamous, non-squamous or not otherwise specified NSCLC with primary resistance to prior PD-1 or PD-L1 inhibitor